BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic candidates for metabolic diseases targeting the biology of human aging. The company leverages a human-first discovery platform analyzing multi-omics data to identify molecular mediators of aging and disease. Lead program BGE-102 is an oral NLRP3 inhibitor in Phase 1 development for atherosclerotic cardiovascular disease and metabolic dysfunction. Secondary program azelaprag is an APJ agonist in Phase 2 development in combination with tirzepatide for obesity in older adults.
BioAge is publicly traded
IPO'd on September 26, 2024
This company is no longer available on our private secondary market. Shares can be traded publicly under BIOA.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2015
Employees
51–200
Total Funding
$491.9M
5 rounds
Total raised $491.9M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
IPO
Date
September 26, 2024
Amount
$198M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| September 26, 2024 | IPO | $198M | — | Public markets |
| February 13, 2024 | Series D | $170M | — | Sofinnova Investments |
| December 3, 2020 | Series C | $90M | — | Andreessen Horowitz, Elad Gil |
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Altos Labs
Longevity biotech backed by Jeff Bezos and Yuri Milner with $3B+ in funding focusing on cellular reprogramming to reverse aging
Insilico Medicine
AI-driven drug discovery platform for aging-related diseases; raised Series E of $110M
Phenome Health
Multi-omics and AI-driven platform for personalized medicine and aging research, led by Lee Hood and James Yurkovich
Life Biosciences
Boston-based biotech focused on epigenetic reprogramming to address aging
DiaCarta
Direct competitor in BioAge Labs space
Mission Bio
Direct competitor in BioAge Labs space
Yes, BioAge is publicly traded under the ticker symbol BIOA on the NASDAQ. The company went public in September 26, 2024.
BioAge trades under the ticker symbol BIOA on the NASDAQ. It began trading in September 26, 2024.
BioAge (BIOA on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker BIOA to place an order.
BioAge went public in September 26, 2024 via ipo. BioAge Labs successfully completed its IPO on September 26, 2024, with shares trading on the Nasdaq Global Select Market under ticker BIOA. The company raised $198M in gross proceeds at $18.00 per share, with final proceeds of $238.3M including underwriter option exercise. In January 2026, BioAge completed a follow-on public offering raising $115M at $19.50 per share.
BioAge raised $491.9M across 5 disclosed funding rounds prior to its public listing.
BioAge was co-founded by Kristen Fortney, and Eric Morgen in 2015.
BioAge is headquartered in Emeryville, CA, US.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.